Prosecution Insights
Last updated: October 04, 2026

Metis Techbio Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Metis Techbio Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner, SHIAO, YIH-HORNG, who is also identified as the busiest examiner with 1 busiest examiner pending case. The concentration of the portfolio is further evidenced by its presence in only 1 distinct art unit. This singular focus suggests that the company's current patent strategy is highly localized within a specific technical niche of the Biotechnology & Pharmaceuticals field.

The alignment of the 1 pending office action with the 1 distinct examiner creates a streamlined but concentrated prosecution environment. Because SHIAO, YIH-HORNG is responsible for the 1 busiest examiner pending case, the outcome of this specific interaction will determine the immediate progress of the company's patent interests. Practitioners should note that with the 1 distinct art unit involved, there is no diversification of examiner perspectives across different USPTO divisions. This lack of variety means that the prosecution success for Metis Techbio Co. Ltd. is entirely dependent on the requirements and tendencies of the assigned personnel.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Double-patenting + other1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SHIAO, YIH-HORNG 1 72.5% +75.9%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18434386 IONIZABLE LIPID COMPOUNDS SHIAO, YIH-HORNG —

Top Art Units

Art UnitApps
1691 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18434386 IONIZABLE LIPID COMPOUNDS SHIAO, YIH-HORNG 1691 §102§103§112DP Non-Final OA — Pending Feb 06, 2024

Managing Metis Techbio Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month